Dublin, March 29, 2023 (GLOBE NEWSWIRE) -- The "Endometriosis Market by Type, Treatment, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The endometriosis market was valued at valued at $1,239.81 million in 2021, and is projected to reach $3,926.41 million by 2031, registering a CAGR of 12.6% from 2022 to 2031.
Major factors driving growth of the endometriosis market include rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population and increasing availability of advanced diagnostic methods such as biopsy, ultrasound and rise in the prevalence of endometriosis.
For instance, according to the WHO 2021 report, about 190 million reproductive-age females have endometriosis, accounting for about 10% of the female population globally.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in advancement in drug delivery technologies, rise in research regarding using combination of drug for the management of endometriosis drives the growth of endometriosis market.
For instance, in January 2022, according to pharmaceutical technology, two GnRH antagonists, ObsEva's Yselty (linzagolix) and Myovant Sciences/Pfizer's Relugolix combination tablet, are set to launch across the seven major pharmaceutical markets, the US, five major European markets (France, Germany, Italy, Spain, and the UK) and Japan, in the next two years. Relugolix will launch in Japan first, entering that market in 2022. These medications will be the first GnRH antagonists launched in the five major European markets and Japan, which will bolster the endometriosis market significantly.
However, the high cost of medicine and low diagnostic rate is expected to hamper the growth of the endometriosis market. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for endometriosis medicine manufacturers worldwide in the future.
Moreover, rapidly advancing global healthcare infrastructure, rise in awareness regarding female reproductive health, increasing government initiatives to raise awareness about women's health in developing countries like India & China drives the growth of endometriosis market.
This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period. In addition, a rise in R&D investments in discovery & development of effective medicine, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries drives the growth of the market.
For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense's Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research.
Furthermore, the rise in key strategies include product launch, partnership, product approval, collaboration, merger, acquisition adopted by key players strengthen demand of medication for the management of endometriosis in the market. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant's commitment to women's health in areas of significant unmet need. Hence, such factors drive the growth of the endometriosis market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endometriosis market analysis from 2021 to 2031 to identify the prevailing endometriosis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the endometriosis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global endometriosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Superficial peritoneal lesion
- Endometriomas
- Others
By Distribution channel
- Hospital pharmacy
- Online pharmacy
- Retail pharmacy
By Treatment
- Oral contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Consilient Health Limited
- Serum Institute of India Pvt. Ltd.
- Abbott Laboratories
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Pfizer Inc.
- AstraZeneca plc
- Abbvie Inc
- Sanofi
- Sun Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd
- Teva Pharmaceutical Industries Limited
Key Market Insights
- On the basis of type, the superficial peritoneal lesion segment was the highest revenue contributor to the market in 2021 and is estimated to reach $2485.74 million by 2031 and is expected to be the fastest-growing segment with a CAGR of 12.8% during the forecast period.
- Based on treatment, the oral contraceptives segment generated maximum revenue in 2021 and gonadotropin-releasing hormone (Gn
- RH) medicines segment is expected to witness highest CAGR of 13.1% during the forecast period.
- Based on end user, the hospital pharmacy segment was the highest revenue contributor to the market in 2021. However, the online pharmacy segment is estimated to be the fastest-growing segment with a CAGR of 13.0% during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 14.3% during the forecast period.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 220 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value (USD) in 2021 | $1239.81 million |
| Forecasted Market Value (USD) by 2031 | $3926.41 million |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ENDOMETRIOSIS MARKET, BY TYPE
CHAPTER 5: ENDOMETRIOSIS MARKET, BY TREATMENT
CHAPTER 6: ENDOMETRIOSIS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: ENDOMETRIOSIS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
Companies Mentioned
- Consilient Health Limited
- Serum Institute of India Pvt. Ltd.
- Abbott Laboratories
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Pfizer Inc.
- AstraZeneca plc
- Abbvie Inc
- Sanofi
- Sun Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd
- Teva Pharmaceutical Industries Limited
For more information about this report visit https://www.researchandmarkets.com/r/ku8cmh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
